年龄相关性眼病研究2第13号报告:眼病与视力损害和死亡风险的关联
AREDS2队列研究纳入4203例至少中期年龄相关性黄斑变性(AMD)患者,中位随访5年,368例(9%)死亡。基线单眼新生血管性AMD、双眼白内障手术史及最佳矫正视力低于20/40与死亡风险升高相关;接受抗血管内皮生长因子治疗的新生血管性AMD患者死亡风险降低。口服omega-3脂肪酸、叶黄素/玉米黄质、锌或β-胡萝卜素对死亡率无统计学显著影响。
要点
- 基线单眼新生血管性AMD与死亡风险升高相关(HR 1.56;95%CI 1.21-2.01;P<0.001)。
- 双眼白内障手术史(HR 1.63;95%CI 1.29-2.07;P<0.001)和BCVA低于20/40(HR 1.56;95%CI 1.06-2.30;P=0.024)与死亡风险升高相关。
- 接受抗VEGF治疗的新生血管性AMD患者死亡风险降低(HR 0.71;95%CI 0.57-0.88;P=0.002)。
核心结论
- 在AREDS2中,晚期AMD、双眼白内障手术及视力低于20/40与生存率下降相关。
- 口服补充omega-3脂肪酸、叶黄素加玉米黄质、锌或β-胡萝卜素对死亡率无统计学显著影响。
研究设计与样本
- 研究设计为队列研究,参与者为至少中期AMD并纳入AREDS2随机对照临床试验(叶黄素/玉米黄质和/或omega-3脂肪酸治疗AMD和白内障)的受试者,共4203例。
- 基线及每年进行眼科检查,包括最佳矫正视力(BCVA)、裂隙灯检查和立体眼底照相,中央判读晚期AMD(中心性地图样萎缩或新生血管性AMD)或人工晶状体眼。
- 死因根据国际疾病分类第9版或第10版编码确定,采用Cox比例风险模型评估全因和特定原因死亡风险,调整年龄、性别、AMD严重程度、视力、白内障手术史及分配的AREDS2研究治疗。
- 分析包括基线协变量:种族、教育程度、吸烟状态、糖尿病和心血管疾病。
主要发现
- 中位随访5年期间,4203例AREDS2参与者中368例(9%)死亡。
- 基线单眼新生血管性AMD患者较无或少量玻璃膜疣者死亡风险统计学显著升高(HR 1.56;95%CI 1.21-2.01;P<0.001)。
- 与基线双眼晶状体眼相比,入组前双眼白内障手术与生存率降低相关(HR 1.63;95%CI 1.29-2.07;P<0.001)。
- 与BCVA 20/40或更好者相比,BCVA低于20/40者生存率降低(HR 1.56;95%CI 1.06-2.30;P=0.024),调整年龄、性别和统计学显著协变量。
- 接受抗血管内皮生长因子治疗的新生血管性AMD患者较未接受者死亡风险降低(HR 0.71;95%CI 0.57-0.88;P=0.002)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the association of mortality with visual acuity (VA) impairment, age-related macular degeneration (AMD), and cataract surgery. DESIGN: Cohort study. PARTICIPANTS: Participants with at least intermediate AMD enrolled in a randomized controlled clinical trial of lutein/zeaxanthin and/or omega-3 fatty acids, the Age-Related Eye Disease Study 2 (AREDS2), for treatment of AMD and cataract. METHODS: Baseline and annual eye examinations included best-corrected visual acuity (BCVA) assessments, slit-lamp examinations, and stereoscopic fundus photographs that were centrally graded for development of late AMD (central geographic atrophy or neovascular AMD) or pseudophakia. Cause-specific mortality was determined on the basis of the International Classification of Diseases 9th or 10th Revision codes. Risk of all-cause and cause-specific mortality was assessed with Cox proportional hazards models adjusted for age, sex, AMD severity, VA, history of cataract surgery, and assigned AREDS2 study treatment. Analyses included baseline covariates: race, education, smoking status, diabetes, and cardiovascular disease. RESULTS: During follow-up (median 5 years), 368 (9%) of the 4203 AREDS2 participants died. Participants with neovascular AMD in 1 eye at baseline had a statistically significant increased risk for mortality compared with participants with no or few drusen (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.21-2.01; P < 0.001). Poorer survival was associated with bilateral cataract surgery before enrollment compared with baseline bilateral phakia (HR, 1.63; 95% CI, 1.29-2.07; P < 0.001) and with BCVA of less than 20/40 compared with participants with 20/40 or better (HR, 1.56; 95% CI, 1.06-2.30; P = 0.024), adjusted for age, sex, and statistically significant covariates. Participants who received antivascular endothelial growth factor therapies for neovascular AMD had decreased mortality compared with those who did not (HR, 0.71; 95% CI, 0.57-0.88; P = 0.002). The association between all-cause mortality and AREDS2 treatment whether assessing the main or individual treatment effect was not significantly different (omega-3 fatty acids main effect HR, 1.18; 95% CI, 0.96-1.45; P = 0.12; lutein/zeaxanthin main effect HR, 1.04; 95% CI, 0.85-1.28; P = 0.71). CONCLUSIONS: In AREDS2, the presence of late AMD, bilateral cataract surgery, and VA less than 20/40 was associated with decreased survival. However, oral supplementation with omega-3 fatty acids, lutein plus zeaxanthin, zinc, or beta-carotene had no statistically significant impact on mortality.
引用
- Papudesu C, Clemons TE, Agrón E, et al. Association of Mortality with Ocular Diseases and Visual Impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology. 2017. PMID: 29153456. doi:10.1016/j.ophtha.2017.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。